288 related articles for article (PubMed ID: 35417004)
1. Report of the First International Symposium on NUT Carcinoma.
French CA; Cheng ML; Hanna GJ; DuBois SG; Chau NG; Hann CL; Storck S; Salgia R; Trucco M; Tseng J; Stathis A; Piekarz R; Lauer UM; Massard C; Bennett K; Coker S; Tontsch-Grunt U; Sos ML; Liao S; Wu CJ; Polyak K; Piha-Paul SA; Shapiro GI
Clin Cancer Res; 2022 Jun; 28(12):2493-2505. PubMed ID: 35417004
[TBL] [Abstract][Full Text] [Related]
2. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
3. Supercharging BRD4 with NUT in carcinoma.
Eagen KP; French CA
Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
[TBL] [Abstract][Full Text] [Related]
4. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
5.
Zheng D; Elnegiry AA; Luo C; Bendahou MA; Xie L; Bell D; Takahashi Y; Hanna E; Mias GI; Tsoi MF; Gu B
Life Sci Alliance; 2024 Jul; 7(7):. PubMed ID: 38724194
[TBL] [Abstract][Full Text] [Related]
6. Primary cutaneous NUT carcinoma with BRD4::NUTM1 fusion.
Shah A; Box A; Brenn T; Flaman A
J Cutan Pathol; 2024 Jun; 51(6):424-429. PubMed ID: 38481096
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
8. The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.
Durall RT; Huang J; Wojenski L; Huang Y; Gokhale PC; Leeper BA; Nash JO; Ballester PL; Davidson S; Shlien A; Sotirakis E; Bertaux F; Dubus V; Luo J; Wu CJ; Keskin DB; Eagen KP; Shapiro GI; French CA
Cancer Res; 2023 Dec; 83(23):3846-3860. PubMed ID: 37819236
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case.
Chen M; Chen X; Zhang Y; Wang W; Jiang L
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6361-6370. PubMed ID: 36752907
[TBL] [Abstract][Full Text] [Related]
10. Primary malignant epithelioid and rhabdoid tumor of bone harboring ZNF532-NUTM1 fusion: the expanding NUT cancer family.
Chien YW; Hsieh TH; Chu PY; Hsieh SM; Liu ML; Lee JC; Liu YR; Ku JW; Kao YC
Genes Chromosomes Cancer; 2019 Nov; 58(11):809-814. PubMed ID: 31334571
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
[TBL] [Abstract][Full Text] [Related]
12. The expanding universe of NUTM1 fusions in pediatric cancer.
Charlab R; Racz R
Clin Transl Sci; 2023 Aug; 16(8):1331-1339. PubMed ID: 37082775
[TBL] [Abstract][Full Text] [Related]
13. NUT carcinoma of the lung.
Lantuejoul S; Pissaloux D; Ferretti GR; McLeer A
Semin Diagn Pathol; 2021 Sep; 38(5):72-82. PubMed ID: 34176698
[TBL] [Abstract][Full Text] [Related]
14. NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum.
Stevens TM; Morlote D; Xiu J; Swensen J; Brandwein-Weber M; Miettinen MM; Gatalica Z; Bridge JA
Mod Pathol; 2019 Jun; 32(6):764-773. PubMed ID: 30723300
[TBL] [Abstract][Full Text] [Related]
15. NUT carcinoma of the parotid gland: report of two cases, one with a rare ZNF532-NUTM1 fusion.
Chen M; Zhao S; Liang Z; Wang W; Zhou P; Jiang L
Virchows Arch; 2022 Apr; 480(4):887-897. PubMed ID: 35064291
[TBL] [Abstract][Full Text] [Related]
16. NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.
French CA
Pathol Int; 2018 Nov; 68(11):583-595. PubMed ID: 30362654
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
Wang R; You J
J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
[TBL] [Abstract][Full Text] [Related]
18. Thyroid Carcinoma with NSD3::NUTM1 Fusion: a Case with Thyrocyte Differentiation and Colloid Production.
Allison DB; Rueckert J; Cornea V; Lee CY; Dueber J; Bocklage T
Endocr Pathol; 2022 Jun; 33(2):315-326. PubMed ID: 34997561
[TBL] [Abstract][Full Text] [Related]
19. High-Grade Spindle Cell Sarcoma of the Scalp With an MGA::NUTM1 Gene Fusion in a Pediatric Patient.
Arellano Zameza P; Karklins SP; Pena J; Bowers NL; Samman A; Ahn C; Sangueza OP
Am J Dermatopathol; 2024 Feb; 46(2):101-103. PubMed ID: 38055974
[TBL] [Abstract][Full Text] [Related]
20. NUT carcinoma, an under-recognized malignancy: a clinicopathologic and molecular series of 6 cases showing a subset of patients with better prognosis and a rare ZNF532::NUTM1 fusion.
Abreu RF; Oliveira TB; Hertzler H; Toledo RN; D'Almeida Costa F; Lopes Pinto CA; Nunes WA; Nascimento AF; French CA; Nascimento AG
Hum Pathol; 2022 Aug; 126():87-99. PubMed ID: 35623465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
